A trial in Italy that's testing Avextra’s cannabis-based medicine for ALS and other neurodegenerative diseases enrolled its ...

People with ALS in the U.S. spend over $47,000 for medical care in the year after diagnosis, more than 3.5 times the average ...

Despite the inaccessibility of an "accessible" bathroom stall, columnist Dagmar Munn finds the humor in the situation.

A new dashboard by the ALS Association offers free and open access to real-world data from more than 4,000 people affected by ...

Researchers developed a cell-free DNA blood test that accurately distinguishes ALS from other neurological diseases and tracks progression.

Researchers have identified new blood and spinal fluid biomarkers that could help track ALS progression and monitor treatment ...

Bristol Myers Squibb have extended their research collaboration aimed at designing and optimizing small-molecule drugs for ...

Diabetes was tied to a 3.3 times greater risk of earlier loss of walking ability in a study of amyotrophic lateral sclerosis ...

ALS is more common in some parts of the U.S. than others and it has a very strong geographic association with MS, a new study ...

EKZ-102, an experimental oral therapy for amyotrophic lateral sclerosis (ALS), is on track to enter early clinical testing in ...

Living with ALS has taken a toll, but columnist Kristin Neva feels like she is doing better now than she has in a long time.

The FDA has granted orphan drug status to the experimental T-cell, or Treg, therapy CK0803, being developed by Cellenkos to treat ALS.